Navigation Links
Amylin Pharmaceuticals Reports Third Quarter Financial Results
Date:10/20/2009

ities is enhanced by this disclosure. In addition, the Company refers to these non-GAAP financial measures with its analysis of the Company's financial performance. These non-GAAP financial measures should be considered in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP.

About Amylin

Amylin Pharmaceuticals is a biopharmaceutical company dedicated to improving lives of patients through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN® (pramlintide acetate) injection and BYETTA® (exenatide) injection. Amylin's research and development activities leverage the Company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego, California. Further information on Amylin Pharmaceuticals is available at www.amylin.com.

This press release contains forward-looking statements about Amylin, which involve risks and uncertainties. Our actual results could differ materially from those discussed herein due to a number of risks and uncertainties, including risks that BYETTA or SYMLIN may be affected by competition, unexpected new data, safety and technical issues, or manufacturing and supply issues; risks that our financial results may fluctuate significantly from period to period and may not meet market expectations; risks that any financial guidance we provide may not be accurate; risks that our clinical trials will not be completed when planned, may not replicate previous results or achieve desired end-points; risks that our preclinical studies may not be predictive; risks that our NDAs for product candidates, such as the exenatide once weekly NDA, or sNDAs for label expansion requests may not be submitted timely or receive FDA approval;
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity
2. Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society
3. Amylin and Lilly Announce Plans to Develop Pen Device for Exenatide Once Weekly
4. Amylin Pharmaceuticals Highlights New Data Supporting Therapeutic Potential of Obesity Pipeline at Obesity 2009
5. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
9. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... 2014 Reportlinker.com announces that a ... its catalogue: Wireless Opportunities in ... UWB WWAN, WMAN, WLAN and other technologies) ... Kalorama Information,s Wireless Opportunities in Healthcare ... WWAN, WMAN, WLAN and other technologies) is ...
(Date:8/20/2014)... 2014   Ventana Medical Systems, Inc.  (Ventana), ... that its VENTANA System for Primary Diagnosis 1 ... Union for routine pathology, including primary diagnosis with ... Virtuoso software coupled with either the VENTANA iScan ... provides automated digital slide creation, case management and ...
(Date:8/20/2014)... 2014  Decision Resources Group finds that ... device market will expand through 2023 as ... fibrillation (AF). The increasing acceptance of ablation ... will spur adoption of premium-priced products designed ... loop diagnostic catheters, cryoablation catheters and contact ...
Breaking Medicine Technology:Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 2Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 3Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 4Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 5Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 6Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 7Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 8Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 9Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 10Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 11Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 12Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 13Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 14Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 15Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 16Full digitization of the anatomic pathology lab is here with the VENTANA System for Primary Diagnosis 2Full digitization of the anatomic pathology lab is here with the VENTANA System for Primary Diagnosis 3Electrophysiology Mapping and Ablation Device Market in Japan to Reach $1.1 Billion by 2023 2Electrophysiology Mapping and Ablation Device Market in Japan to Reach $1.1 Billion by 2023 3
... 30, 2011 /PRNewswire-iReach/ -- CoLucid Pharmaceuticals, ... that it has raised $7.5 million of a ... existing investors to support further late stage development ... Ventures, Domain Associates, Care Capital, Pearl Street Venture ...
... Biopharma, Inc. (OTC.BB: GNBP), a biotechnology company developing targeted ... Shareholders will be posted today to the investor relations ...  In addition, on August 22, 2011, the Company filed ... Report for the three and six months ended June ...
Cached Medicine Technology:CoLucid Pharmaceuticals Raises $7.5 Million of Planned $9.5 Million 2Genesis Biopharma Announces Letter to Shareholders Posted to Website 2Genesis Biopharma Announces Letter to Shareholders Posted to Website 3Genesis Biopharma Announces Letter to Shareholders Posted to Website 4Genesis Biopharma Announces Letter to Shareholders Posted to Website 5
(Date:8/20/2014)... through fast-moving waters may be at risk, suggests new ... salmon encounter turbulent, fast-moving water such as rapids ... upstream using a behaviour known as "burst swimming" that ... sockeye passed through extremely fast-moving water, we started to ... spawning grounds," said Nicholas Burnett, a research biologist at ...
(Date:8/20/2014)... common cause of endophthalmitis, a potentially blinding condition that ... injections, are the well-known staphylococci ("staph") and ... study published in the August issue of Ophthalmology ... of cases at New York Eye and Ear Infirmary ... found that gram-positive bacteria, which include staph and strep ...
(Date:8/20/2014)... By Steven Reinberg ... -- A rare birth disorder that dismantles a baby,s immune ... study of more than 3 million infants says. This ... for the life-threatening but treatable condition known as severe combined ... "People were made aware of this condition by the boy ...
(Date:8/20/2014)... 20, 2014 Get the report here: ... mergermarket presents “Deal Drivers 2014 Half Year Report for ... M&A activity in both North and South America, with ... About Merrill DataSite     , Merrill DataSite is a ... the due diligence process by providing a highly efficient ...
(Date:8/20/2014)... owners looking for ways to make smart changes – and ... check out the latest blog post from Per Wickstrom on ... blog post, which is entitled “Small Changes that Can Have ... , Opportunities for making minor improvements abound, but many ... alert and focused. , Changes shouldn’t be based ...
Breaking Medicine News(10 mins):Health News:Salmon forced to 'sprint' less likely to survive migration 2Health News:Researchers pinpoint most common causes of dangerous eye infection post surgery and trauma 2Health News:Researchers pinpoint most common causes of dangerous eye infection post surgery and trauma 3Health News:'Bubble Boy' Disease May Be More Common Than Thought 2Health News:'Bubble Boy' Disease May Be More Common Than Thought 3Health News:Register to Download Merrill DataSite's Report: Deal Drivers 2014 Half Year Report for the Americas 2Health News:Per Wickstrom’s Latest Blog Post Focuses on Small Changes that Can Have a Big Impact on Business 2
... - including Parkinson's, Alzheimer's, Diffuse Lewy body disease, ... synucleinopathies. Most commonly they become symptomatic due to ... the case of Parkinson's it is dopamine. When ... become impaired, which occurs with oxidation, the eventual ...
... men over the age of 40 years and is the ... goes undetected till it is advanced and beyond cure. However ... and now men over the age of 40 years can ... the most promising "tumour markers" in medicine was developed over ...
... Paul Greengard and Eric Kandel won the Nobel ... transduction in the nervous system." The three Nobel ... prize for their pioneering discoveries "concerning one type ... as slow synaptic transmission," according to the award ...
... that more than two-thirds of births in Russia are marred ... clinic is suffering health problems. , ,The number of ... 30 percent last year, said Olga Frolova, head of the ... that the decline is due to the spread of heavy ...
... drug could make millions of people suffering from ... Disease (COPD) or smoker’s lung, is an irreversible progressive ... emphysema and chronic bronchitis. In tests involving 500 people ... decade, the drug appeared to be safer and better ...
... Researchers at the University of Texas Health Science Center at ... dish from single mouse cells - and they think humans ... direction where they could take ,initial tissue from a [human] ... tooth for them.To accomplish this seemingly futuristic feat, researchers need ...
Cached Medicine News:
... the best EMR value for many medical ... Charting Plus™ relies heavily on a user-friendly ... improve documentation quality and increase productivity in ... specific to your medical specialty. Each program ...
... The Frontier device is a ... with one atrial and two ... chronic atrial fibrillation (AF) who ... ablation and who have NYHA ...
Intrinsic Dual Chamber ICD With MVP Mode (Managed Ventricular Pacing). MVP promotes intrinsic conduction and is clinically proven to reduce unnecessary right ventricular (RV) pacing to approximately...
Provides the security of suture and ease of automated knot tying for vascular closure of 5-8F....
Medicine Products: